KNOWLEDGE PORTAL
on innovation and access to medicines

“The Hospital Clínic de Barcelona-IDIBAPS has developed a new CAR T-cell product, ARI-0002h, and has coordinated a multicentre trial in several Spanish hospitals in order to treat patients with multiple myeloma resistant to the standard treatments. This is the first CAR T-cell product developed in Europe for the disease and its results are encouraging, as all patients improve with treatment and 75% of them maintain their response at 12 months” (Hospital Clínic-IDIBAPS, 2021). The price of Hospital Clínic de Barcelona-IDIBAPS' CAR T-cell therapy is five times lower than the commercial alternative.

ITRC is an "initiative being led by the Indian Council of Medical Research (ICMR), which aims to bring together diverse stakeholders to develop new tools – diagnostics, vaccines and drugs – to enable India to take a leadership role in fast-tracking translational TB research and find solutions for the world. ITRC aims to achieve this goal through adopting an interdisciplinary collaborative approach by harnessing the national and international expertise to advance technology as well as product development by delivering effective diagnostics, shorter drug regimens, efficacious vaccines along with newer interventions for TB control and subsequent elimination of the disease” (ITRC, n.d.).

“The IGI is composed of diverse researchers at the University of California, Berkeley, the University of California, San Francisco, and the University of California, Davis. Together, our scientists have powerful combined expertise. They conduct world-class research, driven by the real possibility of using genome engineering to treat human diseases, end hunger, and respond to climate change. In addition to our scientific efforts, the IGI is committed to advancing public understanding of genome engineering, providing resources for the broader community, and guiding the ethical use of these technologies” (IGI, n.d.).

“IVCC is the only Product Development Partnership (PDP) working in vector control…We work with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. We bring together partners from industry, the public sector and academia to create new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions we accelerate the process from innovation to impact” (IVCC, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190).

“Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient’s bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields” (Inserm, 2021).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190).

“Instituto Butantan is the main producer of immunobiologicals in Brazil. It is responsible for a considerable percentage of the national production of hyperimmune sera and vaccine antigens, which make up the vaccines used in the National Immunization Program (Programa Nacional de Imunizações, PNI) of the Brazilian Ministry of Health. Our technological development activities in the production of health inputs are associated with the production of vaccines, antitoxins and antivenoms, and biopharmaceuticals for human use” (Instituto Butantan, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190).

“In-Q-Tel has served one mission for more than 20 years: to deliver the most sophisticated source of strategic technical knowledge and capabilities to the U.S. government and its allies. In-Q-Tel explores emerging technology and provides insight, powering its partners with the ability to better anticipate and advance national security in the 21st century. Our distinct role at the intersection of the government, venture capital, and the startup world equips In-Q-Tel to make impactful investments” (IQT, n.d.).

“Founded in 2001, InnoCentive was a pioneering business in the use of crowdsourcing for innovation and opportunity scouting. It ran more than 2,000 challenges for organizations including NASA, AstraZeneca, Enel, and VW, boasting a success rate of more than 80%” (Wazoku, n.d.). InnoCentive was acquired by Wazoku in 2020.

This initiative was selected based on its inclusion in the report “RE:ROUTE, A map of the alternative biomedical R&D landscape”, (Kiddell-Monroe, Greenberg, and Basey 2016)

The IMI works to "improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA)” (IMI, n.d.).

This initiative was selected based on its inclusion in the report “RE:ROUTE, A map of the alternative biomedical R&D landscape”, (Kiddell-Monroe, Greenberg, and Basey 2016).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S.  F1000Research 2021, 10:190)

UQ's Institute for Molecular Bioscience is Australia's "#1 research institute for research outputs and a leading institute for commercialisation activity." They are financed by public and philanthropic actors, with a mission "to position Queensland as a global epicentre for drug discovery."

The Instituto Clodomiro Picado ia a research unit of the Universidad de Costa Rica, "responsible for the production of snake antiophidic serums and scientific research on serpents and their venoms". "The Institute produces antivenoms for human and veterinary use in Central America, Ecuador, Nigeria, Sri Lanka, and Papua New Guinea."